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1 Introduction
Placental function may be assessed in high-risk
pregnancies by serum human placental lactogen
(HPL), serum estriol and urinary estriol excretion.
The results of these tests may be influenced by
maternal smoking [16] or drugs, such as corti-
costeroids [6], ampicillin [18], erythromycin [7]
and mandelamine [10]. However, for most drugs
used by pregnant women little or nothing is
known as to whether or not they affect placental
function or its biochemical tests.
Antiepileptic drugs are powerful inducers of
hepatic microsomal enzyme systems [17] and may
alter the metabolism of endogeneous steroid
hormones [17] as well as interfere with oral
contraception [2]. There is a reason to expect
effects on placental function or on its biochemical
tests, too, particularly on the metabolism of
estriol.
The present study is a systematic evaluation of the
placental function in epileptic women, most of
whom took antiepileptic drugs throughout their
pregnancies.
2 Patients and methods
2.1 Patients
A prospective study on 144 consecutive singleton
pregnancies of more than 32 weeks duration in
134 women with epilepsy was carried out in
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1976—79. The patients were seen fortnightly
between 32 to 36 weeks of pregnancy, and weekly
thereafter.
2.2 Controls
After the delivery by each epileptic, one control
pair (mother and child) was obtained at the same
clinic. A control was selected to be the following
parturient who fulfilled the chosen matching
criteria, namely maternal age ± 3 years, same
parity, same fetal sex, and same social class as
determined by the mother's profession using the
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Tab. I. Characteristics of the epileptic patients and the
matched controls.
Age*, years; mean ± SD



























* Matched variable N.S.
standard four-step classification of the Helsinki
City Bureau of Statistics. The controls thus
represented the general parturient population at
the clinic during the study period matched for the
chosen parameters. Characteristics of the epileptics
and their controls appear in Tab. I.
2.3 Criteria for possible drag effects
"Placental function" was evaluated by serum HPL,
24-hour urinary total estriol excretion, placental
weight and birth weight. The possible effects of
antiepileptic drugs on placental function were
expected to appear in the following three ways.
First, as differences between epileptics and con-
trols; second, as differences among epileptics
grouped by the type of their treatment; and third,
as correlations (positive or negative) between
the serum levels of antiepileptic drugs and the
placental variables.
The power of the present study was estimated [12]
as 90% to detect a difference of 50 grams (i.e.
40 % of the standard deviation) in the mean weight
of the placenta between ,ψοιηβη on antiepileptic
drugs and the controls at a p-level of 0.05.
2.4 Measurements
Serum concentrations of phenytoin, pheno-
barbitone, primidone and valproate were measured
by gas chromatography [13, 15]. Carbamazepine
was assessed by spectrophotometry [11]. Total
urinary 24-hour estriol excretion was measured by
radioimmunoassay [1] and serum HPL by the
commercially available Pharmacia kit which is
based on the method of LETCHWORTH [14].
2.5 Calculations and statistics
A computer with BMDP-81 statistical programs [9]
was used. Geometric means of available values of
HPL and estriol were calculated separately for the
9th month (33rd< to 36th week) and the 10th
month (37th to 40th week) of pregnancy in each
patient.
Skewness of the distributions of urinary estriol,
serum HPL and antiepileptic drug levels was
correctable by logarithmic or power transforma-
tions which allowed standard parametric statistical
test.
Differences in placental function variables among
the epileptics grouped by the type of their treat-
ment were tested by one-way analysis of variance.
Correlations between the serum levels of anti-
epileptic drugs and the placental variables were
measured by the standard product-moment
correlation coefficients. To cope with the spurious
correlations expected among the 21 tests of corre-
lation to be performed, a level of significance of
-Ty- = 0.0023 was required for any one correla-
tion before considering it genuine [3].
Tab. II. Serum HPL and total urinary 24-h estriol excretion in epileptic women during late pregnancy.
Month of pregnancy Epileptic patients Reference for normal
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* The 144 epileptic patients were classified as follows: Phenytoin mono therapy (N = 55); carbamazepine monotherapy
(20); combinations including phenobarbitone (26); other combinations (24); and patients not on antiepileptic drugs
(18).
F = F-value. P = probability for occurrence of differences at least as large as those observed among the five groups.
3 Results
No significant differences between the epileptic
mothers and the controls were seen with regard to
gestational age, placental weight and birth weight
(Tab. I). The levels of serum HPL and total urinary
24-hour estriol excretion of women with epilepsy
agreed well with the references (Tab. II). No
notable differences in the serum HPL, urinary
estriol, placental weight or birth weight were
observed among the epileptics grouped by their
drug regimen (Tab. HI).
Serum levels of antiepileptic drugs in late preg-
nancy were often below the "therapeutic" ranges
[8] (Tab. IV). None of the coefficients of correla-
tion between drug levels and serum HPL, urinary
estriol, placental weight and birth weight reached
the pre-established limit of p = 0.0023 (Tab. V).
The positive correlation between serum phenytoin
and birthweight (r = 0.25; ρ = 0.015) was reduced
after an adjustment for gestational age and sex.
Values below the 2.5th percentile of HPL (in
3 patients) and estriol (in 7) appeared associated
with pre-eclampsia and intrauterine growth retarda-
tion but not with maternal antiepileptic treat-
ment.
The incidences of pregnancy complications among
the 144 epileptics and 144 controls (in paren-
thesis) were similar: pregnancy-induced hyper-
tension 8% (10%); albuminuria 3% (3%); intra-
uterine growth retardation, defined as birth weight
below the 10th percentile of the Helsinki standard,
9 % (8 %); placental abruption 1 % (1 %).
4 Discussion
No genuine associations between the types or
serum levels of the antiepileptic drugs and serum
HPL, urinary estriol excretion, placental weight
and birth weight were observed in the present
Tab. IV. Serum levels of antiepileptic drugs in the third trimester of pregnancy
Drug Number of patients Serum level μηιοΙ/1
Levels are medians for 33 to 40th week of pregnancy.
Therapeutic range μιηοΐ
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Transformations prior to analysis: Logarithm of HPL and oestriol; square root of phenytoin and phenobarbitone.
r = product-moment correlation coefficient.
p = two-tailed probability for a coefficient at least as large as observed.
study. This accords with the only similar series
previously reported [5]. The inherent variability of
HPL and estriol is large, and small changes may
remain undetected when the study sample is
relatively small.
An exigent level of significance was required
before considering any of the observed differences
genuine. This was necessary because of the large
number of statistical tests performed. In such a
situation some sporadic associations are to be
expected, and the concentional general level of
p < 0.05 is no more valid [3].
The epileptic patients in the present study seldom
showed very high serum levels of antiepileptic
drugs. The possibility that higher than therapeutic
concentrations of antiepileptic drugs might affect
placental function cannot thus be excluded.
While long-term use of antiepileptic drugs appears
to have little, if any, clinically important effects
on placental function or on its biochemical tests,
short-term use of phenobarbitone in pre-eclamptic
patients may lower serum estriol [4].
Although the present study showed no change in
the total urinary 24-hour estriol excretion, it
does not exclude induction by the drugs in the
metabolism of estriol, such as alterations in the
various glucuronide and sulphate conjugates of
estriol.
Out-of-range values of placental function tests
in epileptic mothers should evidently not be
considered harmless biochemical anomalies due to
the mother's medication as is the case e.g. for
ampicillin [18]. Serum HPL and 24-hour total
urinary estriol can be used in the usual manner to
assess fetoplacental function in epileptic women
who are on long-term treatment with phenytoin,
phenobarbitone or carbamazepine in spite of the
powerful enzyme induction properties of the
drugs.
Summary
Placental function in the presence of antiepileptic drugs
was assessed in 144 unselected late pregnancies of women
with epilepsy. The most common drugs of the mothers
were phenytoin (104 pregnancies), carbamazepine (42)
and phenobarbitone (26). 144 control parturients matched
for maternal age, parity, fetal sex and social class were
also studied.
No significant associations between the types or the
serum concentrations of the mother's antiepileptic drugs
and her serum HPL, 24-hour total urinary estriol excre-
tion, placental weight or her child's birth weight were
observed. However, since the serum levels of antiepileptic
drugs were usually within or below the therapeutic ranges
the study does not exclude the possibility that Very high
drug concentrations might have some effects.
The incidences of common pregnancy complications did
not differ between epileptics and controls. Serum HPL
and urinary estriol values in epileptic women agreed well
with the references for normal.
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It is concluded that the long-term use of antiepileptic
drugs during pregnancy has no clinically important
effects on placental function or on its biochemical tests in
spite of the enzyme induction properties of these drugs.
Values of serum HPL and 24-hour total urinary estriol
excretion can thus be interpreted in the usual manner in
women who are on antiepileptic medication.
Keywords: Antiepileptic drugs, epilepsy, estriol, human placental lactogen, placental function tests, pregnancy.
Zusammenfassung
Bestimmung der Plazentafunktion bei Frauen unter anti-
epileptischer Therapie
Wir untersuchten die Plazentafunktioh bei 144 zufällig
ausgewählten Frauen unter antiepileptischer Medikation
in der Spätschwangerschaft. Die am häufigsten verabreich-
ten Medikamente waren Phenytoin (104 Fälle), Carba-
mazepin (42 Fälle) und Phenobarbital (26 Fälle). Als
Kontrollgruppe untersuchten wir 144 Schwangere, die
bezüglich des mütterlichen Alters, der Anzahl der Gebur-
ten, des fetalen Geschlechts und der sozialen Herkunft
mit den Patientinnen unseres Untersuchungskollektivs
vergleichbar waren und ihnen zugeordnet wurden.
Es fand sich kein signifikanter Zusammenhang zwischen
dem Typ der pharmakologischen Verbindung bzw. ihrer
Serumkonzentration und dem HPL-Wert im Serum, der
Östriol-Ausscheidung im 24-Stunden-Urin, dem Plazenta-
gewicht oder dem kindlichen Geburtsgewicht. Die Serum-
konzentrationen der Antiepileptika lagen jedoch immer
innerhalb oder sogar unterhalb des therapeutischen
Bereichs. Daher können wir nicht ausschließen, daß sehr
hohe Konzentrationen möglicherweise andere Effekte
haben.
Gewöhnliche Schwangerschaftskomplikationen traten bei
der Kontrollgruppe und bei den epileptischen Schwange-
ren gleich häufig auf. Die HPL-Werte im Serum und die
Östriol-Ausscheidung im Urin zeigten eine gute Überein-
stimmung mit den als normal eingestuften Referenz-
werten.
Wir schließen aus unserer Untersuchung, daß eine anti-
epileptische Langzeitmedikation während der Schwanger-
schaft keinen klinisch bedeutsamen Einfluß auf die
Plazentafunktion bzw. ihre biochemische Bestimmung
hat, obwohl die Antiepileptika enzyminduzierende Eigen-
schaften haben. Die Serum-HPL-Werte und die Ausschei-
dung im 24-Stunden-Urin können daher unter antiepilep-
tischer Therapie wie sonst üblich interpretiert werden.
Schlüsselwörter: Antiepüeptika, Epilepsie, Human placental lactogen (HPL), Östriol, Plazentafunktionstests, Schwan-
gerschaft.
Resume
Evaluation de la fonction placentaire chez les femmes
sous traitement anti-epileptique
La fonction placentaire en cours de traitement anti-
epileptique a ete etudiee en fin de grossesse chez 144
femmes epileptiques non selctionnees. Phenytoine
(104 grossesses), carbamazepine (42) et phenobarbital
(26) sont les medicaments les plus utilises. 144 femmes
enceintes temoins apparieees pour Tage maternel, la
parite, le sexe du foetus et la classe sociale ont ete egale-
ment etudiees.
II n'a pas ete mis en evidence de correlation significative
entre le type de medicament anti-epileptique pris par la
femme et sa concentration serique avec PHPL serique,
1'estriol urinaire total des 24 heures, le poids placentaire
ou le poids de naissance du nouveaune. Toutefois, dans
la mesure ou les taux seriques des medicaments anti-
epileptiques se situent au niveau ou en-dessous des taux
therapeutiques, Tetude n'exclut pas la possibilite que des
concentrations elevees puissent entrainer certains effets.
L'incidence des complications habituelles de la grossesse
ne differe pas chez les patientes epileptiques et chez les
temoins. Les valeürs de FHPL serique et de Festriol
urinaire chez les epileptiques sont conformes aux taux
considers comme normaux.
Les auteurs concluent que la prise au long cours d'anti-
epileptiques pendant la grossesse n'a pas d'effet important
en pratique clinique sur la fonction placentaire ou sur ses
tests biochimiques malgre 1'action d'induction enzyma-
tique de ces medicaments. Chez les patientes qui prennent
des anti-epileptiques, les valeürs de THPL serique et de
1'estriol urinaire total des 24 heures peuvent etre inter-
pretees comme dTiabitude.
Mots-cles: Anti-epileptiques, epilepsie, estriol, grossesse, hormone lactogene placentaire, tests de fonction placentaire.
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